With a market capitalization (market cap) of $3.25B — a measure of how much the company is worth — Veracyte, Inc. is the 1750th most valuable company in Healthcare as of August 19, 2026. Shares trade at $40.68, down +3.33% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Visit websiteAs of August 19, 2026, Veracyte, Inc. (VCYT) is worth $3.25B — this is its market capitalization, the total value of all its outstanding shares.
Veracyte, Inc.’s market cap is $3.25B, which ranks it #1750 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Veracyte, Inc. (VCYT) shares trade at $40.68, down 3.33% on the day, as of August 19, 2026.
Veracyte, Inc. trades at a price-to-earnings (P/E) ratio of 48.4, based on its latest share price and annual earnings per share.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025